Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.

Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM.

J Virol. 1998 Feb;72(2):1552-76.

PMID:
9445059
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.

Berman PW, Gray AM, Wrin T, Vennari JC, Eastman DJ, Nakamura GR, Francis DP, Gorse G, Schwartz DH.

J Infect Dis. 1997 Aug;176(2):384-97.

PMID:
9237703
[PubMed - indexed for MEDLINE]
Free Article
3.

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, et al.

JAMA. 1994 Aug 10;272(6):475-80.

PMID:
7913731
[PubMed - indexed for MEDLINE]
4.

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.

Gorse GJ, Patel GB, Newman FK, Belshe RB, Berman PW, Gregory TJ, Matthews TJ.

Clin Diagn Lab Immunol. 1996 Jul;3(4):378-86.

PMID:
8807200
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

AIDS Vaccine Evaluation Group 022 Protocol Team.

J Infect Dis. 2001 Feb 15;183(4):563-70. Epub 2001 Jan 18.

PMID:
11170981
[PubMed - indexed for MEDLINE]
Free Article
7.
8.

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.

Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R.

AIDS Res Hum Retroviruses. 1996 May 20;12(8):683-93.

PMID:
8744579
[PubMed - indexed for MEDLINE]
9.

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.

Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE.

Ann Intern Med. 1996 Aug 15;125(4):270-9.

PMID:
8678389
[PubMed - indexed for MEDLINE]
10.

Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.

Page M, Stebbings R, Berry N, Hull R, Ferguson D, Davis L, Duffy L, Elsley W, Hall J, Ham C, Hassall M, Li B, Mee ET, Quartey-Papafio R, Rose NJ, Mathy N, Voss G, Stott EJ, Almond N.

Retrovirology. 2012 Jul 16;9:56. doi: 10.1186/1742-4690-9-56.

PMID:
22799593
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.

Locher CP, Grant RM, Collisson EA, Reyes-Terán G, Elbeik T, Kahn JO, Levy JA.

AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1685-9.

PMID:
10606091
[PubMed - indexed for MEDLINE]
12.

Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1.

Vinner L, Therrien D, Wee E, Laursen I, Hanke T, Corbet SL, Fomsgaard A.

APMIS. 2006 Oct;114(10):690-9.

PMID:
17004972
[PubMed - indexed for MEDLINE]
13.

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB.

AIDS Res Hum Retroviruses. 1999 Jan 20;15(2):115-32.

PMID:
10029244
[PubMed - indexed for MEDLINE]
15.

Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.

Gorse GJ, Patel GB, Mandava MD, Arbuckle JA, Doyle TM, Belshe RB; National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Vaccine. 2001 Feb 8;19(13-14):1806-19.

PMID:
11166906
[PubMed - indexed for MEDLINE]
16.

Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.

Mossman SP, Bex F, Berglund P, Arthos J, O'Neil SP, Riley D, Maul DH, Bruck C, Momin P, Burny A, Fultz PN, Mullins JI, Liljeström P, Hoover EA.

J Virol. 1996 Mar;70(3):1953-60.

PMID:
8627721
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.

Berman PW, Matthews TJ, Riddle L, Champe M, Hobbs MR, Nakamura GR, Mercer J, Eastman DJ, Lucas C, Langlois AJ, et al.

J Virol. 1992 Jul;66(7):4464-9.

PMID:
1602554
[PubMed - indexed for MEDLINE]
Free PMC Article
18.
19.
20.

Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects.

Shmelkov E, Nadas A, Swetnam J, Zolla-Pazner S, Cardozo T.

PLoS One. 2011;6(11):e27279. doi: 10.1371/journal.pone.0027279. Epub 2011 Nov 4.

PMID:
22076145
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk